Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PRINCIPEN W/ PROBENECID vs PROBENECID AND COLCHICINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ampicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) and inhibiting transpeptidase activity. Probenecid competitively inhibits renal tubular secretion of ampicillin, increasing its plasma concentration and duration.
Probenecid inhibits renal tubular reabsorption of uric acid, increasing its excretion; colchicine binds to tubulin, inhibiting microtubule polymerization and reducing inflammatory response to urate crystals.
Respiratory tract infections,Urinary tract infections,Meningitis,Septicemia,Endocarditis,Gonorrhea (uncomplicated)
Prophylaxis and treatment of acute gout flares,Hyperuricemia associated with gout (probenecid component)
1.5-3 g IM q6h (20 mg/kg/day probenecid component).
One tablet (probenecid 500 mg/colchicine 0.5 mg) orally twice daily for 7 days, then one tablet daily thereafter.
Ampicillin: 1-1.8 hours (prolonged to 4-6 hours with probenecid due to reduced renal clearance). Probenecid: 6-12 hours. Clinical context: extended half-life allows less frequent dosing.
Probenecid: Terminal half-life 6-12 hours (dose-dependent; prolonged at higher doses due to saturable tubular secretion). Colchicine: Terminal half-life 20-40 hours (range 9-30 hours in healthy subjects; prolonged in renal impairment up to 50-60 hours).
Ampicillin is metabolized by hydrolysis to penicilloic acid; probenecid undergoes hepatic metabolism via glucuronidation and oxidation.
Probenecid: hepatic via glucuronidation and oxidation; colchicine: hepatic via CYP3A4 and P-glycoprotein.
Renal: ~60-80% of ampicillin excreted unchanged in urine via tubular secretion and glomerular filtration; probenecid reduces this to ~20-30%. Biliary/fecal: minor, <10%.
Probenecid: Renal excretion of unchanged drug and metabolites; approx. 75-95% of dose eliminated in urine, with <5% as unchanged probenecid. Colchicine: Primarily fecal excretion (about 65%) via biliary excretion; renal excretion accounts for about 20-30% of elimination, with enterohepatic recirculation.
Ampicillin: 15-25% bound to albumin. Probenecid: 85-95% bound to albumin.
Probenecid: 85-95% bound to albumin. Colchicine: 30-50% bound to albumin.
Ampicillin: 0.3-0.4 L/kg (distributes well into extracellular fluid, low CNS penetration unless inflamed meninges).
Probenecid: 0.15 L/kg (indicates distribution primarily in extracellular fluid). Colchicine: 2-8 L/kg (large Vd indicating extensive tissue distribution, particularly into leukocytes and other cells).
Oral: 30-50% for ampicillin (enhanced by probenecid? probenecid does not significantly alter ampicillin absorption). Probenecid: nearly 100% oral.
Probenecid: Oral bioavailability nearly complete (approx. 100%) with extensive metabolism. Colchicine: Oral bioavailability 25-50% (first-pass metabolism and P-glycoprotein efflux in gut); bioavailability listed for oral route.
Cr Cl 30-50 m L/min: 1.5 g IM q8h; Cr Cl 10-29 m L/min: 1.5 g IM q12h; Cr Cl <10 m L/min: 1.5 g IM q24h.
GFR 30-50 m L/min: reduce dose to one tablet daily. GFR 10-29 m L/min: one tablet every 2-3 days. GFR <10 m L/min or dialysis: contraindicated.
No adjustment required for mild to moderate impairment. Severe impairment (Child-Pugh C): consider reducing dose by 25-50%.
Child-Pugh A: no adjustment. Child-Pugh B: reduce colchicine dose by 50%. Child-Pugh C: contraindicated.
Children 2-12 years: 50 mg/kg/day IM in 4 divided doses (probenecid component 25 mg/kg/day). Maximum single dose 2 g.
Not recommended for pediatric use. For acute gout in adolescents, consider alternative therapy.
Reduce dose based on renal function; avoid if Cr Cl <30 m L/min due to probenecid accumulation. Monitor for CNS toxicity.
Start at lowest dose (one tablet daily), monitor renal function and for toxicity due to age-related decreased renal function.
None.
None.
Hypersensitivity reactions including anaphylaxis,Severe cutaneous adverse reactions (SCARs),C. difficile-associated diarrhea,Renal impairment (dose adjustment for ampicillin),Sodium overload with high doses,Allergic cross-reactivity with cephalosporins
Hematologic toxicity (bone marrow suppression), neuromuscular toxicity (especially with renal impairment), severe diarrhea, drug interactions (CYP3A4 and P-gp inhibitors), use caution in elderly and renal/hepatic impairment.
Hypersensitivity to penicillins or probenecid,History of cholestyramine or uricosuric agent hypersensitivity,Severe renal impairment (Cr Cl < 30 m L/min) for probenecid-containing products,Blood dyscrasias or uric acid calculi (probenecid)
Hypersensitivity to probenecid or colchicine, severe renal impairment (Cr Cl <30 m L/min), severe hepatic impairment, concurrent use of P-gp or CYP3A4 inhibitors (e.g., clarithromycin, ketoconazole) in patients with renal/hepatic impairment, blood dyscrasias, uric acid kidney stones.
Take with food or milk to reduce gastrointestinal upset. Avoid high-fat meals as they may delay absorption of ampicillin. Probenecid is not affected by food; however, maintain adequate hydration to prevent crystalluria.
Limit consumption of high-purine foods (e.g., organ meats, anchovies, sardines, red meat, shellfish) as they can exacerbate gout. Avoid alcohol, particularly beer and liquor, which increase uric acid production and reduce probenecid efficacy. No specific food interaction with colchicine; maintain adequate hydration.
FDA Pregnancy Category B: No evidence of risk in humans. Ampicillin crosses placenta; probenecid crosses placenta but no teratogenicity reported. First trimester: No known teratogenic effects. Second/third trimester: Use caution due to potential for altered fetal gut flora. Peripartum: Risk of kernicterus in neonates if maternal hyperbilirubinemia.
First trimester: Data limited; colchicine is associated with increased risk of chromosomal abnormalities in vitro, but human studies show no consistent pattern of major malformations. Probenecid is not teratogenic in animal studies. Second and third trimesters: No evidence of fetal harm from either drug, but insufficient data. Avoid during pregnancy unless benefit outweighs risk.
Ampicillin excreted in breast milk in low levels (M/P ratio 0.02-0.1); probenecid probably excreted but data limited. Compatible with breastfeeding; monitor infant for diarrhea, rash, or candidiasis. Theoretical risk of kernicterus in jaundiced infants if probenecid displaces bilirubin.
Colchicine is excreted into human milk in low concentrations; M/P ratio not established. Probenecid is excreted in milk in amounts likely negligible (M/P ratio ~0.5). Both considered compatible with breastfeeding, but monitor infant for diarrhea (colchicine).
Increased renal clearance in pregnancy may reduce ampicillin levels; consider higher doses or more frequent intervals for severe infections. Probenecid dose adjustment not typically required, but monitor for efficacy. Use standard doses for UTI unless resistant organisms suspected.
No specific pharmacokinetic data in pregnancy; however, increased renal clearance and volume of distribution in pregnancy may reduce probenecid and colchicine plasma concentrations. Consider dose adjustment based on clinical response and toxicity monitoring, but no standard recommendations exist.
Principen w/ Probenecid combines ampicillin, a broad-spectrum penicillin, with probenecid to prolong ampicillin serum levels by inhibiting renal tubular secretion. Use in penicillin-allergic patients is contraindicated. Probenecid may reduce excretion of other drugs (e.g., methotrexate, NSAIDs). Monitor renal function; probenecid is contraindicated in patients with uric acid kidney stones or blood dyscrasias. Administer with food if GI upset occurs. Synergistic with aminoglycosides but physically incompatible; do not mix in IV solutions.
Colchicine levels can increase with concurrent use of P-glycoprotein inhibitors (e.g., amiodarone, verapamil, clarithromycin) or CYP3A4 inhibitors (e.g., ketoconazole, ritonavir). Probenecid can raise plasma concentrations of penicillins, cephalosporins, and indomethacin. Monitor for colchicine toxicity (nausea, diarrhea, myopathy) especially in renal impairment; reduce dose in chronic kidney disease. Probenecid may inhibit renal excretion of drugs and can cause uricosuria, so ensure high fluid intake to prevent urate stones.
Take this medication exactly as prescribed, even if you feel well.,Complete the full course to prevent antibiotic resistance.,May cause diarrhea; contact your doctor if it is severe or contains blood.,Avoid alcohol while taking this medication.,Inform your doctor if you have kidney disease, gout, or a history of penicillin allergy.,Probenecid may increase effects of warfarin; monitor for bleeding.,Drink plenty of fluids to prevent kidney stones while on probenecid.
Take with food or milk to reduce gastrointestinal upset.,Drink plenty of water (at least 8 glasses per day) while taking probenecid.,Colchicine can cause severe diarrhea or vomiting; stop and call your doctor if this occurs.,Avoid alcohol, which can worsen gout and interfere with probenecid's effect.,Do not start new medications (especially antibiotics, antifungal, or heart medications) without consulting your doctor due to drug interactions.,Report unexplained muscle pain, weakness, numbness, or tingling immediately (colchicine myopathy).,Keep this and all medications out of reach of children.
"Edoxaban, a direct factor Xa inhibitor, may inhibit organic anion transporters (OATs) involved in the renal excretion of probenecid, leading to increased probenecid plasma concentrations. Elevated probenecid levels can enhance its uricosuric effect and potentially increase the risk of adverse effects such as gastrointestinal disturbances and hypersensitivity reactions. Clinicians should be aware of this interaction when coadministering these agents, particularly in patients with renal impairment."
"Acemetacin, a nonsteroidal anti-inflammatory drug (NSAID) and prodrug of indomethacin, reduces renal clearance of probenecid by inhibiting tubular secretion and possibly competing for organic anion transporters. This leads to increased plasma concentrations of probenecid, prolonging its half-life and enhancing its uricosuric effect. Clinically, this interaction may result in elevated risk of probenecid toxicity, including gastrointestinal discomfort, rash, or rare blood dyscrasias, while also potentially increasing the anti-inflammatory effects of acemetacin."
"Cilostazol, a phosphodiesterase III inhibitor, can inhibit the renal tubular secretion of probenecid, a uricosuric agent, thereby decreasing its clearance and increasing its serum concentration. This elevation may potentiate the effects and toxicity of probenecid, including an increased risk of uric acid nephropathy and gastrointestinal disturbances. The interaction is of particular concern in patients with renal impairment or those receiving concurrent nephrotoxic drugs."
"Colchicine may decrease the cardiotoxic effects of Deslanoside by reducing its absorption or altering its pharmacokinetics, potentially leading to subtherapeutic digoxin levels and reduced efficacy. This interaction could increase the risk of atrial fibrillation or heart failure exacerbation in patients requiring cardiac glycoside therapy. Clinical outcomes may include loss of rate control in atrial fibrillation or decreased inotropic support in heart failure."
"Colchicine, a substrate of CYP3A4 and P-glycoprotein (P-gp), can inhibit CYP2D6 and to a lesser extent CYP3A4 at therapeutic concentrations. Fluvoxamine, a potent CYP1A2 and moderate CYP2C9/3A4 inhibitor, may have its serum concentration increased by colchicine via competition for CYP3A4 and P-gp efflux, although colchicine's inhibition of CYP3A4 is weak. This interaction could potentiate fluvoxamine's serotonergic adverse effects, including serotonin syndrome, as well as increase the risk of QT prolongation and sedation. However, clinical significance is generally low unless high doses of colchicine are used."
"Colchicine and sildenafil both utilize cytochrome P450 3A4 (CYP3A4) for metabolism. Concurrent administration can lead to competitive inhibition of CYP3A4, resulting in increased plasma concentrations of sildenafil. Elevated sildenafil levels may potentiate its vasodilatory effects, increasing the risk of hypotension, priapism, and other adverse events."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PRINCIPEN W/ PROBENECID vs PROBENECID AND COLCHICINE, answered by our medical review team.
PRINCIPEN W/ PROBENECID is a Uricosuric that works by Ampicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs) and inhibiting transpeptidase activity. Probenecid competitively inhibits renal tubular secretion of ampicillin, increasing its plasma concentration and duration.. PROBENECID AND COLCHICINE is a Uricosuric that works by Probenecid inhibits renal tubular reabsorption of uric acid, increasing its excretion; colchicine binds to tubulin, inhibiting microtubule polymerization and reducing inflammatory response to urate crystals.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PRINCIPEN W/ PROBENECID and PROBENECID AND COLCHICINE depend on the specific clinical indication. These are both Uricosuric agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PRINCIPEN W/ PROBENECID is: 1.5-3 g IM q6h (20 mg/kg/day probenecid component).. The standard adult dose of PROBENECID AND COLCHICINE is: One tablet (probenecid 500 mg/colchicine 0.5 mg) orally twice daily for 7 days, then one tablet daily thereafter.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining PRINCIPEN W/ PROBENECID and PROBENECID AND COLCHICINE. Probenecid inhibits OAT3-mediated renal tubular secretion of phenylbutyrate and its active metabolite phenylacetate, leading to a significant increase in systemic exposure of these metabolites. Elevated phenylacetate levels can enhance the risk of hyperammonemia, neurotoxicity, and gastrointestinal adverse effects, particularly in patients with urea cycle disorders. Concurrent use requires close monitoring for signs of toxicity and dose adjustment of phenylbutyric acid. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. PRINCIPEN W/ PROBENECID is classified as Category A/B. FDA Pregnancy Category B: No evidence of risk in humans. Ampicillin crosses placenta; probenecid crosses placenta but no teratogenicity reported. First trimester: No known teratoge. PROBENECID AND COLCHICINE is classified as Category A/B. First trimester: Data limited; colchicine is associated with increased risk of chromosomal abnormalities in vitro, but human studies show no consistent pattern of major malformatio. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.